![](https://assets.reachrx.ai/images/10.1111%E2%98%8Djocd.16434/_page_0_Picture_0.jpeg)

Do not print this page

To view your printing options, return to the document and click the print option in the menu in the top right corner of the page.

Journal of Cosmetic Dermatology

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Omega‐3 fatty acids (ω‐3 FA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are essential nutrients known for their anti‐inflammatory properties, which involve reducing pro‐inflammatory cytokines, eicosanoids, and insulin‐like growth factor‐1. This suggests their potential to alleviate acne severity, especially when deficits are present.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>To elevate EPA/DHA levels in acne patients through dietary intervention and supplementation, observing subsequent clinical effects.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Over 16 weeks, 60 patients without prescription medication (<jats:italic>n</jats:italic> = 23 acne comedonica [AC], <jats:italic>n</jats:italic> = 37 acne papulopustulosa [AP]) adhered to a Mediterranean diet, incorporating oral algae‐derived ω‐3 FA supplementation (600 mg DHA/300 mg EPA week 1–8, 800 mg DHA/400 mg EPA week 8–16). At four visits (V1–V4), blood EPA/DHA levels were tracked using the HS‐omega 3 index® (EPA/DHA (%) of total identified fatty acids in erythrocytes; target 8%–11%, deficit &lt;8%, severe deficit &lt;4%), alongside clinical assessments and standardized questionnaires.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>At baseline, 98.3% of patients had an EPA/DHA deficit, with the mean HS‐omega 3 index® rising from 4.9% at V1 to 8.3% at V4 (<jats:italic>p</jats:italic> &lt; 0.001). AC showed significantly higher indices than AP at V4 (<jats:italic>p</jats:italic> = 0.035). Objective improvements in both inflammatory and non‐inflammatory lesions were observed (<jats:italic>p</jats:italic> &lt; 0.001). While self‐reported appearance worsened in four patients, overall quality of life improved (<jats:italic>p</jats:italic> &lt; 0.001), particularly in AP. Dietary triggers were more clearly defined than beneficial foods. Intake of cow's milk and dairy products reduced (<jats:italic>p</jats:italic> &lt; 0.001). Compliance was good; no adverse events were reported.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Many acne patients have a ω‐3 FA deficit. The HS‐omega 3 index® can be increased by a Mediterranean diet and oral supplementation with algae‐derived ω‐3 FA. Acne severity improved significantly in patients with target ω‐3 FA levels.</jats:p></jats:sec>

publication_history

received

accepted

published

Clinical effects of omega‐3 fatty acids on acne vulgaris

J Dtsch Dermatol Ges

Confusion about the effects of omega‐3 fatty acids: contemplation of study data taking the omega‐3 index into consideration

Internist (Berl)

Effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris

J Ayub Med Coll Abbottabad

Omega-3 fatty acids (ω-3 FA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are essential nutrients known for their anti-inflammatory properties, which involve reducing pro-inflammatory cytokines, eicosanoids, and insulin-like growth factor-1. This suggests their potential to alleviate acne severity, especially when deficits are present.
To elevate EPA/DHA levels in acne patients through dietary intervention and supplementation, observing subsequent clinical effects.
Over 16 weeks, 60 patients without prescription medication (n = 23 acne comedonica [AC], n = 37 acne papulopustulosa [AP]) adhered to a Mediterranean diet, incorporating oral algae-derived ω-3 FA supplementation (600 mg DHA/300 mg EPA week 1-8, 800 mg DHA/400 mg EPA week 8-16). At four visits (V1-V4), blood EPA/DHA levels were tracked using the HS-omega 3 index® (EPA/DHA (%) of total identified fatty acids in erythrocytes; target 8%-11%, deficit <8%, severe deficit <4%), alongside clinical assessments and standardized questionnaires.
At baseline, 98.3% of patients had an EPA/DHA deficit, with the mean HS-omega 3 index® rising from 4.9% at V1 to 8.3% at V4 (p < 0.001). AC showed significantly higher indices than AP at V4 (p = 0.035). Objective improvements in both inflammatory and non-inflammatory lesions were observed (p < 0.001). While self-reported appearance worsened in four patients, overall quality of life improved (p < 0.001), particularly in AP. Dietary triggers were more clearly defined than beneficial foods. Intake of cow's milk and dairy products reduced (p < 0.001). Compliance was good; no adverse events were reported.
Many acne patients have a ω-3 FA deficit. The HS-omega 3 index® can be increased by a Mediterranean diet and oral supplementation with algae-derived ω-3 FA. Acne severity improved significantly in patients with target ω-3 FA levels.

Exploring the potential of omega-3 fatty acids in acne patients: A prospective intervention study.

Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study

Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions